In a groundbreaking development, a baby has become the first person to receive a personalized CRISPR gene-editing treatment for a devastating genetic disease. Little KJ Muldoon, who is almost ten months old, has shown positive progress after undergoing three doses of the gene-editing therapy. However, it is too early to determine if this treatment can be considered a definitive cure, according to Rebecca Ahrens-Nicklas, one of Muldoon’s physicians at Children’s Hospital of Philadelphia.
The therapy developed for Muldoon was specific to his genetic mutation and is unlikely to be applicable to other individuals. An international team of clinicians and researchers collaborated to create this bespoke treatment within a remarkably short period of six months. The drug, detailed in the New England Journal of Medicine, highlights the potential of personalized CRISPR therapies for rare genetic disorders.
While previous CRISPR treatments have targeted common genetic conditions like sickle-cell anemia, Muldoon’s therapy was uniquely tailored to address a specific mutation affecting his ability to process proteins. He inherited two mutations that hindered the production of a crucial enzyme, leading to high levels of ammonia in his blood and posing a severe risk to his health.
The traditional treatment for Muldoon’s condition would have been a liver transplant, but the urgency of his situation prompted his medical team to explore alternative options. Leveraging a CRISPR-based technique known as base editing, they devised a strategy to correct his genetic mutation through targeted DNA alterations. With the approval of Muldoon’s parents, the team embarked on an intensive research and development process, involving preclinical studies in animal models and collaboration with industry partners.
After receiving the tailored gene-editing therapy, Muldoon demonstrated improved tolerance to protein intake and reduced dependence on medication to manage his condition. With each subsequent dose of the treatment, his clinicians have been able to gradually reduce his medication dosage, indicating promising results in his ongoing recovery.
While the success of Muldoon’s personalized CRISPR therapy offers hope for treating rare genetic diseases, challenges remain in scaling up such individualized treatments due to cost and logistical constraints. Nonetheless, the progress made in Muldoon’s case underscores the potential of CRISPR technology in revolutionizing precision medicine for genetic disorders.
As Muldoon continues to achieve milestones in his recovery, his parents are grateful for the advancements in medical science that have enabled their son to thrive. The journey of this pioneering gene-editing treatment serves as a beacon of hope for future applications of CRISPR therapies in addressing complex genetic conditions.
This article, originally published in Nature magazine on May 15, 2025, highlights the transformative impact of personalized CRISPR gene-editing treatments in the realm of rare genetic diseases.
